Cost of Preimplantation Cardiac Imaging in Patients Referred for a Primary-Prevention Implantable Cardioverter-Defibrillator

American Journal of Cardiology

Volumn 102, Issue 5, 2008, Pages 588-592

  Krahn, Andrew D ^a   Hoch, Jeffrey S ^b   Rockx, Marie Antoinette ^a   Leong Sit, Peter ^a   Gula, Lorne J ^a   Yee, Raymond ^a   Skanes, Allan C ^a   Klein, George J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST; COST CONTROL; DEFIBRILLATOR; ECHOCARDIOGRAPHY; ECONOMIC ASPECT; EVALUATION; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HUMAN; IMAGING; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

COSTS AND COST ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; VENTRICULAR FUNCTION;

EID: 51749099360     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.067     Document Type: Article

References (30)

1. Gregoratos G., Abrams J., Epstein A.E., Freedman R.A., Hayes D.L., Hlatky M.A., Kerber R.E., Naccarelli G.V., Schoenfeld M.H., Silka M.J., et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 (2002) 2145-2161
2. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W., and Andrews M.L. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
3. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss A.J., Myerburg R.J., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48 (2006) e247-e346
4. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Levine J.H., Saksena S., Waldo A.L., Wilber D., Brown M.W., and Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. [see comments]. N Engl J Med 335 (1996) 1933-1940
5. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
6. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., and Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 (1999) 1882-1890
7. Tang A.S., Ross H., Simpson C.S., Mitchell L.B., Dorian P., Goeree R., Hoffmaster B., Arnold M., and Talajic M. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol 21 suppl A (2005) S11-S18
8. Buxton A.E. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator?. Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator. Circulation 111 (2005) 2537-2549
9. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
10. Kadish A., Dyer A., Daubert J.P., Quigg R., Estes N.A., Anderson K.P., Calkins H., Hoch D., Goldberger J., Shalaby A., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
11. Hohnloser S.H., Kuck K.H., Dorian P., Roberts R.S., Hampton J.R., Hatala R., Fain E., Gent M., and Connolly S.J. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
12. Cohn J.N., Johnson G., Ziesche S., Cobb F., Francis G., Tristani F., Smith R., Dunkman W.B., Loeb H., Wong M., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
13. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., and DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
14. Hjalmarson A., Goldstein S., Fagerberg B., Wedel H., Waagstein F., Kjekshus J., Wikstrand J., El Allaf D., Vitovec J., Aldershvile J., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 283 (2000) 1295-1302
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
16. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., Schnittger I., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
17. Gottsauner-Wolf M., Schedlmayer-Duit J., Porenta G., Gwechenberger M., Huber K., Glogar D., Probst P., and Sochor H. Assessment of left ventricular function: comparison between radionuclide angiography and semiquantitative two-dimensional echocardiographic analysis. Eur J Nucl Med 23 (1996) 1613-1618
18. Nichols K.J., Bacharach S.L., Bergmann S.R., Cullom S.J., Ficaro E.P., Galt J.R., Heller G.V., Links J., and Machac J. Instrumentation quality assurance and performance. J Nucl Cardiol 13 (2006) e25-e41
19. Schwarz K.Q., Bezante G.P., Chen X., Villa G., and Brunelli C. Contrast harmonic color Doppler left ventriculography: machine-interpreted left ventricular ejection fraction compared with equilibrium-gated radionuclide ventriculography. J Am Soc Echocardiogr 13 (2000) 368-378
20. van Royen N., Jaffe C.C., Krumholz H.M., Johnson K.M., Lynch P.J., Natale D., Atkinson P., Deman P., and Wackers F.J. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77 (1996) 843-850
21. Agresti A., and Coull B.A. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 52 (1988) 119-126
22. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
23. Mushlin A.I., Hall W.J., Zwanziger J., Gajary E., Andrews M., Marron R., Zou K.H., and Moss A.J. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97 (1998) 2129-2135
24. Sheldon R., O'Brien B.J., Blackhouse G., Goeree R., Mitchell B., Klein G., Roberts R.S., Gent M., and Connolly S.J. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 104 (2001) 1622-1626
25. Lynd L.D., and O'Brien B.J. Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence. J Cardiovasc Electrophysiol 14 suppl (2003) S99-S103
26. Larsen G., Hallstrom A., McAnulty J., Pinski S., Olarte A., Sullivan S., Brodsky M., Powell J., Marchant C., Jennings C., and Akiyama T. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 105 (2002) 2049-2057
27. O'Brien B.J., Connolly S.J., Goeree R., Blackhouse G., Willan A., Yee R., Roberts R.S., and Gent M. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 103 (2001) 1416-1421
28. Stanton M.S., and Bell G.K. Economic outcomes of implantable cardioverter-defibrillators. Circulation 101 (2000) 1067-1074
29. Mushlin A.I., Hall W.J., Zwanziger J., Gajary E., Andrews M., Marron R., Zou K.H., and Moss A.J. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation 97 (1998) 2129-2135
30. Nanthakumar K., Epstein A.E., Kay G.N., Plumb V.J., and Lee D.S. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol 44 (2004) 2166-2172